<div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0380" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0380">7.8 Cardiac Amyloidosis</h3>
            <div id="acsec11.8" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.8">
                <div id="acsectitle0385" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0385">7.8.1 Diagnosis of Cardiac Amyloidosis</h4>
            <div id="undtbl34" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl34">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0690">Recommendations for Diagnosis of Cardiac Amyloidosis</p>
                            <p id="tspara0695">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0685" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1685"><strong>Patients for whom there is a clinical suspicion
                                                        for cardiac amyloidosis</strong><a class="ref table-fn"
                                                        id="dtbl3fnlowast"
                                                        href="javascript:popRef('dtbl3fnlowast')"><strong><sup>∗</sup></strong></a>
                                                    (<a class="tab-link" href="#bib991"
                                                        data-tab="pane-pcw-references">1-5</a>) <strong>should have
                                                        screening for serum and urine monoclonal light chains with serum
                                                        and urine immunofixation electrophoresis and serum free light
                                                        chains</strong> (<a class="tab-link" href="#bib996"
                                                        data-tab="pane-pcw-references">6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0690" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1690"><strong>In patients with high clinical suspicion for
                                                        cardiac amyloidosis, without evidence of serum or urine
                                                        monoclonal light chains, bone scintigraphy should be performed
                                                        to confirm the presence of transthyretin cardiac
                                                        amyloidosis</strong> (<a class="tab-link" href="#bib997"
                                                        data-tab="pane-pcw-references">7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0695" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1695"><strong>In patients for whom a diagnosis of transthyretin
                                                        cardiac amyloidosis is made, genetic testing with <i>TTR</i>
                                                        gene sequencing is recommended to differentiate hereditary
                                                        variant from wild-type transthyretin cardiac
                                                        amyloidosis</strong> (<a class="tab-link" href="#bib998"
                                                        data-tab="pane-pcw-references">8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn id="dtbl3fnlowast">
                            <p id="ntpara0080">∗ LV wall thickness ≥14 mm in conjunction with fatigue, dyspnea, or
                                edema, especially in the context of discordance between wall thickness on echocardiogram
                                and QRS voltage on ECG, and in the context of aortic stenosis, HFpEF, carpal tunnel
                                syndrome, spinal stenosis, and autonomic or sensory polyneuropathy.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6015"><strong>Synopsis</strong></p>
            <p id="p6020">Cardiac amyloidosis is a restrictive cardiomyopathy with extracellular myocardial protein
                deposition, most commonly monoclonal immunoglobulin light chains (amyloid cardiomyopathy [AL-CM]) or
                transthyretin amyloidosis (ATTR-CM). ATTR can be caused by pathogenic variants in the transthyretin gene
                <i>TTR</i> (variant transthyretin amyloidosis, ATTRv) or wild-type transthyretin (wild-type
                transthyretin amyloidosis, ATTRwt). A diagnostic approach is outlined in <a data-tab="pane-pcw-Figures"
                    href="#fig13" id="fig13R" class="">Figure 13</a> (<a class="tab-link" href="#bib999"
                    data-tab="pane-pcw-references">9</a>).</p>
            <section class="article-section__inline-figure">
                <figure id="fig13" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/9ecdd3d4-dd37-4e3c-aea3-2bad8312b333/gr13.jpg"
                        data-lg-src="/cms/asset/c81d8cf5-03a8-4857-96e8-81c9ff842ecc/gr13.jpg" alt="Figure 13">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/c81d8cf5-03a8-4857-96e8-81c9ff842ecc/gr13.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig13&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 13</span></strong>
                        <p>Diagnostic and Treatment of Transthyretin Cardiac Amyloidosis Algorithm</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> AF indicates atrial
                            fibrillation; AL-CM, amyloid cardiomyopathy; ATTR-CM, transthyretin amyloid cardiomyopathy;
                            ATTRv, variant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis;
                            CHA<sub>2</sub>DS<sub>2</sub>-VASc, congestive heart failure, hypertension, age ≥75 years,
                            diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74
                            years, sex category; ECG, electrocardiogram; H/CL, heart to contralateral chest; HFrEF,
                            heart failure with reduced ejection fraction; IFE, immunofixation electrophoresis; MRI,
                            magnetic resonance imaging; NYHA, New York Heart Association; PYP, pyrophosphate; Tc,
                            technetium; and TTR, transthyretin.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p6025"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1315" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6030">Diagnosis of ATTR-CM requires a high index of suspicion. LV thickening (wall
                                thickness ≥14 mm) along with fatigue, dyspnea, or edema should trigger consideration of
                                ATTR-CM, especially with discordance between wall thickness on echocardiogram and QRS
                                voltage on ECG (<a class="tab-link" href="#bib1000"
                                    data-tab="pane-pcw-references">10</a>), or other findings such as apical sparing of
                                LV longitudinal strain impairment on echocardiography and diffuse late-gadolinium
                                enhancement on cardiac MRI. ATTR-CM is prevalent in severe aortic stenosis (<a
                                    class="tab-link" href="#bib991" data-tab="pane-pcw-references">1</a>), HFpEF (<a
                                    class="tab-link" href="#bib992" data-tab="pane-pcw-references">2</a>), carpal tunnel
                                syndrome (<a class="tab-link" href="#bib993" data-tab="pane-pcw-references">3</a>),
                                lumbar spinal stenosis (<a class="tab-link" href="#bib994"
                                    data-tab="pane-pcw-references">4</a>), and autonomic or sensory polyneuropathy (<a
                                    class="tab-link" href="#bib995" data-tab="pane-pcw-references">5</a>). Practically,
                                screening for the presence of a monoclonal light chain and technetium pyrophosphate
                                (<sup>99m</sup>Tc-PYP) scan can be ordered at the same time for convenience, but the
                                results of the <sup>99m</sup>Tc-PYP scan are interpreted only on the context of a
                                negative monoclonal light chain screen. <sup>99m</sup>Tc-PYP scans may be positive even
                                in AL amyloidosis (<a class="tab-link" href="#bib997"
                                    data-tab="pane-pcw-references">7</a>) and, thus, a bone scintigraphy scan alone,
                                without concomitant testing for light chains, cannot distinguish ATTR-CM from AL-CM.
                                Serum free light chain (FLC) concentration and serum and urine immunofixation
                                electrophoresis (IFE) are assessed to rule out AL-CM. IFE is preferred because serum
                                plasma electrophoresis and urine plasma electrophoresis are less sensitive. Together,
                                measurement of serum IFE, urine IFE, and serum FLC is &gt;99% sensitive for AL
                                amyloidosis (<a class="tab-link" href="#bib996" data-tab="pane-pcw-references">6</a>,<a
                                    class="tab-link" href="#bib1001" data-tab="pane-pcw-references">11</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6035">The use of <sup>99m</sup>Tc bone-avid compounds for bone scintigraphy allows
                                for noninvasive diagnosis of ATTR-CM (<a class="tab-link" href="#bib997"
                                    data-tab="pane-pcw-references">7</a>). <sup>99m</sup>Tc compounds include PYP,
                                3,3-diphosphono-1,2-propanodicarboxylic acid, and hydromethylene diphosphonate, and PYP
                                is used in the United States. In the absence of a light-chain abnormality, the
                                <sup>99m</sup>Tc-PYP scan is diagnostic of ATTR-CM if there is grade 2/3 cardiac uptake
                                or an H/CL ratio of &gt;1.5. In fact, the presence of grade 2/3 cardiac uptake in the
                                absence of a monoclonal protein in serum or urine has a very high specificity and
                                positive predictive value for ATTR-CM (<a class="tab-link" href="#bib997"
                                    data-tab="pane-pcw-references">7</a>). SPECT is assessed in all positive scans to
                                confirm that uptake represents myocardial retention of the tracer and not blood pool or
                                rib uptake signal (<a class="tab-link" href="#bib1002"
                                    data-tab="pane-pcw-references">12</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6040">If ATTR-CM is identified, then genetic sequencing of the <i>TTR</i> gene will
                                determine if the patient has a pathological variant (ATTRv) or wild-type (ATTRwt)
                                disease (<a class="tab-link" href="#bib1002" data-tab="pane-pcw-references">12</a>).
                                Differentiating ATTRv from ATTRwt is important because confirmation of ATTRv would
                                trigger genetic counseling and potential screening of family members and therapies,
                                inotersen and patisiran, which are presently approved only for ATTRv with polyneuropathy
                                (<a class="tab-link" href="#bib1003" data-tab="pane-pcw-references">13</a>,<a
                                    class="tab-link" href="#bib1004" data-tab="pane-pcw-references">14</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.8" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.8">
                <div id="acsectitle0390" class="anchor-spacer"></div>
            </h3>